



PATIENT CARD

HEMGENIX® (etranacogene dezaparvovec)

Carry this card with you at all times after administration of HEMGENIX® and show it to any person who may give you medical care, such as doctors and/or nurses.

INFORMATION FOR PATIENTS

- Make sure you undergo regular blood tests and examinations as directed by your doctor.
- Please seek immediate medical advice for any symptoms suggestive of a blood clot such as sudden chest pain, shortness of breath, sudden onset of muscle weakness, loss of sensation and/or balance, decreased alertness, difficulty in speaking, pain/tenderness in the leg, increased warmth and red or discoloured skin on the leg, or swelling of one or both legs.
- After a male patient has been treated with HEMGENIX®, the patient and any female partner must avoid pregnancy for 12 months. You should use effective contraception (e.g., barrier contraception such as a condom or diaphragm).
- Avoid taking alcohol, medications, herbal products or supplements which can cause liver damage. Consult your doctor if you are unsure before taking any new medication.
- **Do not donate blood, semen, organs, tissues, and cells for transplantation.**

INFORMATION FOR HEALTHCARE PROFESSIONALS

This patient has been treated with HEMGENIX®, a liver-directed gene therapy product that expresses the human coagulation Factor IX for the treatment of Haemophilia B.

If alanine aminotransferase (ALT) levels are elevated within the first 3 months after HEMGENIX® treatment, the patient may need to undergo treatment with corticosteroids to minimise the risk of hepatotoxicity with HEMGENIX®.

In case of emergency, or questions concerning treatments possibly interacting with HEMGENIX® treatment, use the following contact information:

Patient's name:

Date of HEMGENIX® administration (DD/MM/YYYY):

Haemophilia treating physician's name:

Gene therapy physician's name (if different):

Phone number/Email:

Phone number/Email:

Institution:

Institution:

Contact in case of emergency: